Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 StudiesBusiness Wire • 09/09/20
Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal TrialBusiness Wire • 09/09/20
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic CoughBusiness Wire • 09/08/20
Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine developmentCNBC • 09/08/20
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and CareBusiness Wire • 09/02/20
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great ChoiceZacks Investment Research • 09/01/20
Merck Is Now Pursuing Two Coronavirus Vaccines — Is Merck Stock A Buy?Investors Business Daily • 08/27/20
Merck Analyst Raises Price Target Ahead Of Upcoming Antiviral Trial Results, PresentationBenzinga • 08/25/20